Author

Vassilios A Sevastianos

"Evaggelismos" General Hospital, Athens, Greece - Cited by 1,278 - Internal Medicine - Hepatology

Biography

Vassilios A Sevastianos currently works in the Department of Internal Medicine and Hepatology at Evangelismos General Hospital, Greece. His research interests include Hepatology, Internal Medicine, Chronic Hepatitis C, Liver Diseases, Cirrhosis. International experience includes various programs, contributions and participation in different countries for diverse fields of study. Doing research from so many years in the field of Food science and Nutrition.
Title
Cited by
Year
Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir
SJ Hadziyannis, V Sevastianos, I Rapti, D Vassilopoulos, E HadziyannisGastroenterology 143 (3), 629-636. e1, 2012201
345
2012
Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis
GV Papatheodoridis, N Chrysanthos, S Savvas, V Sevastianos, G Kafiri, ...Journal of viral hepatitis 13 (5), 303-310, 2006200
156
2006
Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen–negative chronic hepatitis B …
EK Manesis, GV Papatheodoridis, V Sevastianos, E Cholongitas, ...The American journal of gastroenterology 98 (10), 2261-2267, 2003200
152
2003
MELD vs Child-Pugh and creatinine-modified Child-Pugh score for predicting survival in patients with decompensated cirrhosis
GV Papatheodoridis, E Cholongitas, E Dimitriadou, G Touloumi, ...World journal of gastroenterology: WJG 11 (20), 3099, 2005200
129
2005
Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era
GV Papatheodoridis, V Sevastianos, AK BurroughsAmerican Journal of Transplantation 3 (3), 250-258, 2003200
70
2003
SUSTAINED BIOCHEMICAL AND VIROLOGICAL REMISSION AFTER DISCONTINUATION OF 4 TO 5 YEARS OF ADEFOVIR DIPIVOXIL (ADV) TREATMENT IN HBEAGNEGATIVE CHRONIC HEPATITIS B: 114
SJ Hadziyannis, V Sevastianos, IN Rapti, N TassopoulosHepatology 44, 231A-232A, 2006200
53
2006
Atherosclerosis as extrahepatic manifestation of chronic infection with hepatitis C virus
T Voulgaris, VA SevastianosHepatitis Research and Treatment 2016, 2016201
34
2016
Pegylated interferon-2b-associated autoimmune thrombocytopenia in a patient with chronic hepatitis C
VA Sevastianos, M Deutsch, SP Dourakis, EK ManesisOfficial journal of the American College of Gastroenterology| ACG 98 (3 …, 2003200
31
2003
Nonalcoholic fatty liver disease: from clinical recognition to treatment
VA Sevastianos, SJ HadziyannisExpert Review of Gastroenterology & Hepatology 2 (1), 59-79, 2008200
29
2008
18 OUTCOME OF HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHB) 5 YEARS AFTER DISCONTINUATION OF LONG TERM ADEFOVIR DIPIVOXIL (ADV) TREATMENT
S Hadziyannis, V Sevastianos, I RaptiJournal of Hepatology, S9-S10, 2009200
23
2009
Hepatitis C, systemic inflammation and oxidative stress: correlations with metabolic diseases
VA Sevastianos, TA Voulgaris, SP DourakisExpert Review of Gastroenterology & Hepatology 14 (1), 27-37, 2020202
21
2020
Malnutrition and sarcopenia in advanced liver disease
VA Sevastianos, SP DourakisJ Nutr Food Sci 6 (487), 2, 2016201
14
2016
Alcoholic liver disease: A clinical review
VA Sevastianos, SP DourakisJ. Nutr. Food Sci 6, 508, 2016201
12
2016
Pathogenesis, diagnosis and therapy of infections complicating patients with chronic liver disease
VA Sevastianos, SP DourakisAnnals of gastroenterology, 2003200
12
2003
Ischemic stroke as the first manifestation of hepatic epithelioid hemangioendothelioma
P Zis, A Assi, D Kravaritis, VA SevastianosJournal of Stroke and Cerebrovascular Diseases 23 (3), e237-e240, 2014201
10
2014
Common ABCB1 polymorphisms in Greek patients with chronic hepatitis C infection: A comparison with hyperlipidemic patients and the general population
E Gbandi, A Goulas, V Sevastianos, S Hadziyannis, A Panderi, ...Pharmacological Reports 6, 476-42, 2016201
8
2016
Can Nucleos (t) ide Analogue (NA) Therapy Ever be Stopped in HBeAg-Negative Chronic Hepatitis B?
SJ Hadziyannis, D Vassilopoulos, V Sevastianos, E HadziyannisCurrent Hepatology Reports 13, 256-263, 2014201
7
2014
Deep jaundice in an adolescent
M Deutsch, S Dourakis, V Sevastianos, A Kaloterakis, S HadziyannisPostgraduate Medical Journal 9 (935), 544, 2003200
7
2003
HERACLIS‐TAF: a multi‐centre prospective cohort study on 2‐year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone …
GV Papatheodoridis, K Mimidis, S Manolakopoulos, N Gatselis, J Goulis, ...Alimentary Pharmacology & Therapeutics 56 (4), 02-12, 2022202
7
2022
Treatment-related compared to spontaneously-occurring HBsAg loss in HBeAg-negative chronic hepatitis B
E Hadziyannis, V Sevastianos, A Georgiou, SJ HadziyannisHepatology 0 (4), 09A-10A, 2009200
5
2009

Referred From: https://scholar.google.com/citations?user=X86ukZIAAAAJ&hl=en

Cited by
Citations 1278
h-index 14
i10-index 17
Open Access Journals